Pharmacokinetics of parent silymarin flavonolignans
Data are presented as geometric means (95% CI).
SA | SB | ISA | ISB | SC | SD | ||
|---|---|---|---|---|---|---|---|
| Healthy | Cmax (ng/ml) | 12 (2, 67) | 9 (2, 43) | 3 (1, 14) | N.D. | N.D. | N.D. |
| AUC0-24h (ng · h/ml) | 33 (2, 488) | 23 (2, 302) | 3 (1, 16) | N.D. | N.D. | N.D. | |
| CL/F (l/h) | 970 (168, 5590)a | 2354 (308, 18,034)a | 2835b | N.D. | N.D. | N.D. | |
| Noncirrhotic | Cmax (ng/ml) | 13 (1, 269) | 12 (1, 252) | 5 (0.3, 86) | 5 (0.3, 85) | 9 (1, 119) | 4 (0.4, 39) |
| AUC0-24h (ng · h/ml) | 13 (1,156) | 16 (1, 397) | 5 (0.4, 57) | 5 (0.3, 63) | 13 (1, 244) | 5 (0.3, 90) | |
| CL/F (l/h) | 713 (344, 1488)c | 1581 (584, 4316)c | 720b | 281b | 1095 (508, 2357)c | 484b | |
| Cirrhotic | Cmax (ng/ml) | 69 (45, 107) | 33 (3, 385) | 11 (1, 156) | 15 (2, 104) | 5 (0.3, 91) | N.D. |
| AUC0-24h (ng · h/ml) | 41 (3, 549) | 149 (115, 195) | 12 (1, 191) | 16 (2, 115) | 7 (0.2, 251) | N.D. | |
| CL/F (l/h) | 509 (389, 667) | 1156 (614, 2165)a | 505 (208, 1222)c | 402 (240, 675)a | 541b | N.D. | |
| NAFLD | Cmax (ng/ml) | 61 (24, 157) | 40 (14, 110) | N.D. | 5 (0.3, 62) | N.D. | N.D. |
| AUC0-24h (ng · h/ml) | 40 (19, 43) | 84 (43, 166) | N.D. | 4 (0.4, 51) | N.D. | N.D. | |
|
| CL/F (l/h) | 904 (454, 1800) | 3019 (1422, 6438) | N.D. | 349a | N.D. | N.D. |
Not determined (N.D.) indicates concentrations below limit of quantitation. Geometric means for CL/F reflect n = 5 unless otherwise specified: a n = 4, b the average of only two values, c n = 3.